This manuscript explores advancements beyond conventional chemotherapy, focusing on antibody-based therapies such as blinatumomab and inotuzumab ozogamicin, CAR T-cell therapy, and emerging strategies targeting apoptosis, epigenetics, and the mTOR pathway to exploit therapeutic vulnerabilities in B-ALL. Here, MTOR is linked to acute lymphoblastic leukemia.